Mizuho raised the firm’s price target on Cencora to $224 from $192 and keeps a Neutral rating on the shares. The analyst increased estimates following the company’s “strong” fiscal Q1 results, citing core growth in Cencora’s U.S. Healthcare Solutions segment and better than expected operating leverage. The firm also sees an improved generic inflationary environment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on COR: